Latest news with #Borregaard
Yahoo
2 days ago
- Business
- Yahoo
Borregaard ASA: Change in Group Executive Management
Knut-Harald Bakke has been appointed EVP BioSolutions, effective 1 August 2025. He will also join the Group Executive Management on the same date. Bakke succeeds Tom Erik Foss-Jacobsen, who will assume the role of CEO on 1 August (see stock exchange release dated 23 May 2025). Bakke currently serves as Director of Investor Relations and has previously held the position of Energy Director at Borregaard. Prior to joining the company in 2019, he held senior leadership roles at Norsk Hydro, where he was responsible for global energy market operations. He holds an MSc in Industrial Economics and Technology Management from the Norwegian University of Science and Technology (NTNU). Borregaard will initiate a process to appoint a new Director of Investor Relations. In the interim, CFO Per Bjarne Lyngstad will assume the responsibility from 1 August. Contacts:Dag Arthur Aasbø, SVP Organisation and Public Affairs, +47 918 34 108Per Bjarne Lyngstad, CFO, +47 952 44 515 This information is subject to the disclosure requirements pursuant to Section 5-12 of the Norwegian Securities Trading Act.
Yahoo
27-05-2025
- Business
- Yahoo
Borregaard ASA: Reporting of transactions in Borregaard ASA's shares made by person discharging managerial responsibilities
John Arne Ulvan, member of the board of Borregaard ASA, has on 27 May 2025 purchased 2,000 shares in Borregaard ASA at a price of NOK 188.04 per share. Following this transaction, John Arne Ulvan owns 5,500 shares in Borregaard ASA. The shares are purchased at Oslo Stock Exchange. Shareholder-elected board members shall use 20% of their gross remuneration to purchase shares in the company until they own shares equal in value to one year's gross board remuneration. The shares shall be retained for as long as the board member serves on the board. Please see attached notifications for persons discharging managerial responsibilities in Borregaard in accordance with Regulation EU 596/2014 (MAR) article 19. Borregaard ASASarpsborg, 27 May 2025 Contact:Lotte Kvinlaug, Investor Relations Officer, +47 922 86 909 This information is subject to the disclosure requirements pursuant to Section 3-1 of the Norwegian Securities Trading Act, cf. Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (market abuse regulation) Article Borregaard ASA - Notification John Arne UlvanError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
23-05-2025
- Business
- Yahoo
Borregaard ASA: Tom Erik Foss-Jacobsen appointed CEO of Borregaard
Tom Erik Foss-Jacobsen has been appointed CEO of Borregaard ASA. He succeeds Per A. Sørlie, who will retire after 26 years in the position (see notice to Oslo Stock Exchange 3 December 2020). The appointment will be effective 1 August 2025. 'I am pleased that Tom Erik Foss-Jacobsen has accepted the position as CEO of Borregaard. With Foss-Jacobsen, Borregaard will get a leader with in-depth understanding of the business and previous experience from significant parts of Borregaard's international operations. Over several years, he has delivered strong results and has made a significant contribution to developing a robust and common culture and strategic understanding throughout the company. We are confident that he has the qualities necessary to further develop the company in the years to come,' says Helge Aasen, chair of Borregaard's Board of Directors. Tom Erik Foss-Jacobsen is currently Executive Vice President (EVP) and head of the BioSolutions (lignin-based biopolymers and vanillin products), a position he has held since 2019. Prior to that, he was EVP and head of BioMaterials (speciality cellulose and bioethanol) in Borregaard. Foss-Jacobsen holds a master's degree in international marketing and strategy and a bachelor's degree in civil engineering. He has more than 25 years' experience from Borregaard, including 21 years in leadership roles. 'I have been fortunate to be part of an exciting journey in Borregaard's commercial organisation. I'm proud of how Borregaard's highly competent organisation has continuously advanced our specialisation strategy by growing high-value business, driving diversification, and delivering solid results. I approach the responsibilities of my new role with humility and a deep sense of commitment. With a comprehensive understanding of our organisation's operations and strategic objectives, I am confident in our collective ability to continue driving sustainable growth and creating value for both Borregaard and its stakeholders,' says Foss-Jacobsen. Per A. Sørlie has worked in Borregaard for 35 years and will leave the company at the end of September 2025. 'Per A. Sørlie has made significant contributions to Borregaard over more than 26 years as CEO, following nine years in key leadership roles within the company. He has been instrumental in shaping Borregaard's strategy, leading the transformation into a bio-based specialty chemicals company with strong global market positions. Since the company's listing on the Oslo Stock Exchange in 2012, Sørlie has played a pivotal role in driving substantial profit growth and increasing shareholder value. Moreover, he has fostered a robust commercial culture and developed leaders capable of advancing the business in the years ahead,' says Aasen. The Board will grant Foss-Jacobsen stock options at the accession date 1 August in accordance with the company's remuneration policy for long-term incentive schemes. Contacts:Director Investor Relations, Knut-Harald Bakke, +47 905 79 164Director Communications, Tone Horvei Bredal, +47 924 67 711 This information is subject to the disclosure requirements pursuant to Section 5 -12 of the Norwegian Securities Trading Act. Sign in to access your portfolio
Yahoo
23-04-2025
- Business
- Yahoo
Borregaard ASA: Invitation to Q1 2025 announcement
23 April 2025: Borregaard ASA ('Borregaard', OSE ticker: BRG) Presentation of Q1 2025 results Borregaard will report first quarter 2025 results on Wednesday 30 April 2025 at 07:00 CEST. A stock exchange announcement will be made. A press release, the quarterly report and a presentation will be made available on A presentation of the first quarter 2025 results will also be held at 08:30 CEST at SEB, Filipstadveien 10, Bygg B, Oslo. Attendance in person is possible. The presentation can be followed live on web-TV at It will be possible to ask questions via the web. All presentations will be held in English. For more information about Borregaard ASA, please visit Contact:Lotte Kvinlaug, Investor Relations Officer, +47 922 86 909 This information is subject to the disclosure requirements pursuant to Section 5 -12 of the Norwegian Securities Trading Act. Sign in to access your portfolio
Yahoo
20-03-2025
- Business
- Yahoo
3 European Stocks That May Be Undervalued By As Much As 39.6%
As European markets grapple with concerns over U.S. trade tariffs and monetary policy uncertainties, the pan-European STOXX Europe 600 Index has recently experienced a decline, reflecting broader economic apprehensions. In such an environment, identifying undervalued stocks can be crucial for investors seeking opportunities; these stocks often exhibit strong fundamentals or potential for growth that may not yet be fully recognized by the market. Name Current Price Fair Value (Est) Discount (Est) Telefonaktiebolaget LM Ericsson (OM:ERIC B) SEK83.02 SEK164.54 49.5% Wienerberger (WBAG:WIE) €35.24 €69.57 49.3% CTT Systems (OM:CTT) SEK228.00 SEK443.67 48.6% Net Insight (OM:NETI B) SEK4.92 SEK9.58 48.6% Storytel (OM:STORY B) SEK90.85 SEK180.37 49.6% Star7 (BIT:STAR7) €6.30 €12.42 49.3% InTiCa Systems (XTRA:IS7) €4.22 €8.25 48.9% Fodelia Oyj (HLSE:FODELIA) €7.12 €13.91 48.8% MilDef Group (OM:MILDEF) SEK208.50 SEK405.57 48.6% Galderma Group (SWX:GALD) CHF96.38 CHF189.25 49.1% Click here to see the full list of 208 stocks from our Undervalued European Stocks Based On Cash Flows screener. Let's take a closer look at a couple of our picks from the screened companies. Overview: Borregaard ASA develops, produces, and markets specialized biomaterials and biochemicals globally, with a market cap of NOK17.56 billion. Operations: The company's revenue segments consist of Bio Materials at NOK2.62 billion, Bio Solutions at NOK4.24 billion, and Fine Chemicals at NOK799 million. Estimated Discount To Fair Value: 39.6% Borregaard is trading at NOK176, significantly below its estimated fair value of NOK291.48, suggesting it may be undervalued based on cash flows. Analysts forecast earnings growth of 14.6% annually, outpacing the Norwegian market's 8%. Recent financials show Q4 sales increased to NOK1.74 billion from NOK1.61 billion year-over-year, though full-year net income slightly declined to NOK823 million from NOK870 million. The proposed dividend for 2024 is set at NOK4.25 per share. Our earnings growth report unveils the potential for significant increases in Borregaard's future results. Click here to discover the nuances of Borregaard with our detailed financial health report. Overview: AddLife AB (publ) and its subsidiaries supply equipment, consumables, and reagents to the healthcare sector, research institutions, educational entities, and the food and pharmaceutical industries with a market cap of SEK18.21 billion. Operations: The company's revenue is primarily derived from its Labtech segment, which generated SEK3.80 billion, and its Medtech segment, which contributed SEK6.50 billion. Estimated Discount To Fair Value: 32% AddLife, trading at SEK149.4, is valued below its estimated fair value of SEK219.82, highlighting potential undervaluation based on cash flows. Analysts project significant earnings growth of 30.22% annually over the next three years, surpassing the Swedish market's average. Recent results show Q4 sales increased to SEK2.82 billion from SEK2.54 billion year-over-year, with net income improving to SEK94 million from a loss previously reported; a dividend of SEK0.75 per share was proposed for 2024. Upon reviewing our latest growth report, AddLife's projected financial performance appears quite optimistic. Unlock comprehensive insights into our analysis of AddLife stock in this financial health report. Overview: Colt CZ Group SE, along with its subsidiaries, is involved in the production, purchase, and sale of firearms, ammunition products, and tactical accessories across various regions including the Czech Republic, Canada the United States Europe Africa Asia and other international markets; it has a market cap of CZK43.31 billion. Operations: The company's revenue primarily comes from its Firearms and Accessories segment, which generated CZK26.22 billion. Estimated Discount To Fair Value: 30.9% Colt CZ Group, trading at CZK767, is significantly undervalued based on discounted cash flow analysis, with an estimated fair value of CZK1110.53. Despite a decline in profit margins from last year and high debt relative to operating cash flow, earnings are forecast to grow 58.3% annually over the next three years—outpacing the Czech market's growth rate. However, shareholders faced substantial dilution recently and dividends remain unsustainably covered by earnings or free cash flows. Our comprehensive growth report raises the possibility that Colt CZ Group is poised for substantial financial growth. Click here and access our complete balance sheet health report to understand the dynamics of Colt CZ Group. Unlock our comprehensive list of 208 Undervalued European Stocks Based On Cash Flows by clicking here. Are any of these part of your asset mix? Tap into the analytical power of Simply Wall St's portfolio to get a 360-degree view on how they're shaping up. Streamline your investment strategy with Simply Wall St's app for free and benefit from extensive research on stocks across all corners of the world. Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include OB:BRG OM:ALIF B and SEP:CZG. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Sign in to access your portfolio
